Partner Content Partner Content MHRA, Pfizer, Autolus and Tusk Theraputics Sign Up for Immun... MHRA, Pfizer & Autolus Sign Up for Immuno-Oncology 2018
Partner Content Partner Content Less than 4 Weeks until Immuno-Therapy Experts Gather at the... Less than 4 Weeks until Immuno-Oncology Conference
Partner Content Partner Content Invitation from Chair of this year’s Immuno-Oncology Confere... Invitation from Chair of Immuno-Oncology Conference
News JPM: AbbVie pays $650m upfront for RemeGen cancer drug AbbVie joins the ranks of companies developing cancer drugs that target both PD-1 and VEGF, via a $5.6bn licensing deal with China's RemeGen.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
